Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.
about
Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trialExpression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USAEffects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysisThe selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in miceProstate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysisCOX-2 and cancer: a new approach to an old problemDo altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors?Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expressionCOX2 genetic variation, NSAIDs, and advanced prostate cancer riskAlterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinomaNon-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analogEffect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2Partial prostatectomy using Nd:YAG laser for management of canine prostate carcinoma.Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.Antibiotic and anti-inflammatory use and the risk of prostate cancerRibosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells.Cytotoxic necrotizing factor from Escherichia coli induces RhoA-dependent expression of the cyclooxygenase-2 Gene.Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer.Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progressionBone marrow fat: linking adipocyte-induced inflammation with skeletal metastasesNonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohortPreventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model.2-[4-(Methyl-sulfon-yl)phen-yl]acetonitrile.Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasionTumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma.Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs.The expression of COX-2 in VEGF-treated endothelial cells is mediated through protein tyrosine kinaseAspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO studyCOX-2 expression and tumor angiogenesis in colorectal cancerCan we prevent prostate cancer? Rationale and current status of prostate cancer chemoprevention.Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II studyCytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancerNon-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer.Involvement of COX-2/PGE2 signalling in hypoxia-induced angiogenic response in endothelial cellsThe target of arachidonic acid pathway is a new anticancer strategy for human prostate cancerRoles of Eicosanoids in Prostate Cancer.Blood level omega-3 Fatty acids as risk determinant molecular biomarker for prostate cancer.
P2860
Q24627834-CEA2CB78-FF0A-4661-B376-C57610498E6DQ24793622-1D8B74DA-B243-4DDE-A575-94224E1E23FCQ24796323-2D94E203-DC2B-4047-8F26-8F4BC4560D32Q25255790-3166587E-62DB-4614-A25C-570910B32E72Q28166676-8F98E382-2413-4675-9B62-834252E7B4EAQ28191533-2124021F-87FB-46B8-ABC5-B10A53A64E10Q28195582-BF234D4F-14D1-4115-A419-68C6C68E07B4Q28199319-57959688-1433-4F7A-8975-39C256E4FEEFQ28217972-979E98D6-AE62-419B-AEC6-C052FB2193B2Q28360358-67BBD259-111E-4949-92DE-4524F0D4B9BCQ28363575-15577271-4495-414D-9071-08F317CB10D9Q28484672-7C50940A-7CBA-4136-BAD5-749B2C8167C3Q30523968-4D591416-E668-4370-9C2B-3570699D18C9Q33245878-E3583DEE-B09F-41BE-A660-C242F3C14803Q33249461-469343E1-FB69-4D79-A48F-49B5FD26607DQ33431458-2B3F78AF-8A13-48D1-8CAD-A6E70AA7D491Q33433522-3C9635BA-7BC7-411B-BB68-859789A77CBBQ33552763-1AF2F7C3-A53A-4459-A08F-4E5DA591BF52Q33561179-B6756199-AFD0-4994-AB09-FCAB96E63471Q33647551-D9B76FA4-8D13-4C2B-9CC1-015344C0E03CQ34008146-9970883F-3627-4B5E-941D-7C446259D22DQ34014610-E42EE1B7-8361-4FA7-90CD-700128795361Q34132305-76316736-4102-48FF-8E36-3B9A68715102Q34422409-B07872A1-1DDF-4BE7-89F0-3CDE23CB93BBQ34591055-8F15D528-859F-46D0-84E5-349135EB1525Q34638589-34E3AA1B-330E-40BC-BB16-AFA181858D5FQ34646962-570ECB67-CFF8-46EE-AA5A-672B5A87CAB9Q35010488-7133B4D7-6E02-4D8A-A2F3-0B37B0555648Q35132201-B8D8A983-F0DB-4031-B36E-BD12048D2F83Q35609405-0B09DDBF-4729-4FB1-ADC1-251BA3B11E8FQ36075269-791E1BBC-84A6-4B37-9260-FA1AA58317A5Q36076514-2B88FCF4-CD5A-4932-B91F-976296499AFFQ36129601-1D35BAAE-965D-4F31-9D6C-6241C6D79F02Q36611472-FC0E7688-96F4-4EA1-849C-E3A9BAAE3C8FQ37020802-1C56A162-ED14-4F1B-9BE8-6DECC44A1797Q37155271-37406397-3097-489C-8651-E62C99A4A72FQ37294251-5DB27AB4-0026-4209-859D-DC4E11734E3BQ37586958-0960E7E8-130A-4B80-A596-FD1D98F9995AQ37592857-F14912D1-542D-417E-A580-E5C95FD30182Q39714298-B7BDA608-906D-46B7-AAD1-CD339D9CEACD
P2860
Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Inhibition of cyclooxygenase-2 ...... th of prostate cancer in vivo.
@en
type
label
Inhibition of cyclooxygenase-2 ...... th of prostate cancer in vivo.
@en
prefLabel
Inhibition of cyclooxygenase-2 ...... th of prostate cancer in vivo.
@en
P2093
P1476
Inhibition of cyclooxygenase-2 ...... th of prostate cancer in vivo.
@en
P2093
P304
P356
10.1097/00005392-200009010-00056
P407
P433
P577
2000-09-01T00:00:00Z